LPTX News

Leap Therapeutics Reports Second Quarter 2025 Financial Results

CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap Highlights: Board of Directors initiated...

August 14, 2025Earnings

Leap Therapeutics Q1 EPS $(0.37) Beats $(0.38) Estimate

LPTX

May 13, 2025

HC Wainwright & Co. Reiterates Neutral on Leap Therapeuticsto Neutral

LPTX

March 27, 2025

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

LPTX

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ongoing business development plans.

March 26, 2025

Leap Therapeutics Today Presented Updated Preliminary Data From Sirexatamab Colorectal Cancer Study

LPTX

March 26, 2025

HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Maintains $5.5 Price Target

LPTX

November 15, 2024